Preliminary Research of Cardiovascular Events Risk Assessment in Patients With Advanced Heart Failure by Dynamic Changes of Three Biomarkers

张荣成,张宇辉,张健,黄燕,郭潇,王运红,安涛,周琼,赵雪梅

DOI: https://doi.org/10.3969/j.issn.1000-3614.2015.05.005

2015-01-01

Abstract:Objective: To observe the dynamic changes of 3 plasma biomarkers in treating the patients with advanced heart failure (HF) and to explore the predictive value of those changes for the occurrence of cardiovascular (CV) events. Methods: A total of 64 consecutive patients with advanced HF treated in our hospital from 2013-10 to 2014-01 were enrolled. The plasma levels of N-terminal pro-B–type natriuretic peptide (NT-proBNP), BNP and soluble ST2 (sST2) were examined at admission, 3 days and 6 days after admission respectively. The patients were followed-up for 6 months, the end points included re-admission for worsening HF, cardiac transplantation or cardiovascular death. The patients were divided into 2 groups as With CV event group, n=24 and Without CV event group,n=40. Results: With 6 days of treatment, the above plasma biomarkers had no significant changes in With CV event group, while in Without CV event group, plasma levels of NT-proBNP, BNP were obviously decreased,P<0.05, but sST2 level remained similar. Receiver operating characteristic (ROC) curve analysis indicated that compared the baseline of admission, after 6 days of treatment, the above biomarkers may better predict the occurrence of CV events, the predictive value of sST2 was even higher than NT-proBNP and BNP at different stage during the follow-up period, allP<0.05. Conclusion: Plasma levels of NT-proBNP and sST2 had the stronger predictive value for CV event occurrence in advanced HF patients after proper treatment. The sST2 level may assess the risk of CV events in advanced HF patientsmore effectively.